Difference between revisions of "Bleomycin (Blenoxane)"

Revision as of 23:41, 23 November 2014

General information

Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.^[1]
Route: IV, IM, SC, intrapleural
Extravasation: irritant

1 unit of bleomycin = 1 mg of bleomycin

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

7/31/1973: Initial FDA approval

References

[insert-1] 1.0 ^1.1 Bleomycin (Blenoxane) package insert (locally hosted backup)

[2] Bleomycin (Blenoxane) patient drug information (Chemocare)

[3] Bleomycin (Blenoxane) patient drug information (UpToDate)

[1]

[2]

[3]

@@ Line 31: / Line 31: @@
 [[Category:Drug index]]
 [[Category:Chemotherapy]]
+[[Category:Intracavitary chemotherapy]]
+[[Category:Intramuscular chemotherapy]]
+[[Category:Intravenous chemotherapy]]
+[[Category:Subcutaneous chemotherapy]]
+[[Category:Irritant chemotherapy]]
 [[Category:DNA synthesis inhibitors]]
-[[Category:Irritant chemotherapy]]
 [[Category:Aggressive Non-Hodgkin lymphoma medications]]